Buy Rating Justified by Arcturus Therapeutics’ Market Potential and Strong Vaccine Efficacy
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report) today and set a price target of ...
PipelineReview.com19h
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of ...
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared ...
Delaware County Daily Times22h
Night Words for October: A bright comet vaults into the evening sky
Also on October evenings, standing high in the east-southeast is the most distinctive landmark of autumn nights: the Great ...
Arcturus Therapeutics: A Strong Buy on Superior Vaccine Efficacy and Market Potential
Wells Fargo analyst Yanan Zhu has assigned their bullish stance on ARCT stock, giving a Buy rating on September 19. Yanan Zhu has given his ...